ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) said the first patient in the Phase Ib/II clinical trial of IMM2510 in combination with chemotherapy for the first-line treatment of non-small cell lung cancer was successfully dosed, according to a Monday filing with the Hong Kong bourse.

IMM2510 is a bispecific molecule developed by the group that uses a mAbTrap structure to target two proteins: VEGF, which promotes blood vessel growth, and PD-L1, which suppresses the immune system, reducing blood flow to tumors and leads to their shrinking, the filing said.